mTORC1 shutdown unleashes TFEB to drive triple-negative breast cancer invasion
Dev Cell. 2025 Apr 7;60(7):979-981. doi: 10.1016/j.devcel.2025.03.006.
Published on April 8, 2025
ABSTRACT
The PI3K/AKT/mTOR pathway is considered a key therapeutic target in triple-negative breast cancer (TNBC). In this issue of Developmental Cell, Remy et al. challenge this idea by demonstrating that mTORC1 inhibition activates TFEB, promoting MT1-MMP exocytosis, ECM degradation, and increased cell invasion, especially when combined with chemotherapy.
PMID:40199239 | DOI:10.1016/j.devcel.2025.03.006
Latest Publications
- Disrupting Complement-Inflammation Positive Feedback Circuit via Oligonucleotide Hydrogel Microspheres for Reversing Joint Inflammation
- Vimentin in the tumor microenvironment: orchestrating invasion, immunity, and metabolism
- Structural and functional characterization of a metagenomically derived γ-type carbonic anhydrase and its engineering into a hyperthermostable esterase
- Calponin isoforms define the cell-type-specific organization and dynamics of actomyosin bundles
- Dynamics of gut metabolome and microbiota maturation during early life